A5210: PHASE IB/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是确定几种剂量水平的AMD 11070的安全性（起始剂量由携带X4嗜性病毒的HIV感染受试者接受A5191给药10天的结果确定），并确定每个队列中携带A5191的受试者比例。AMD 11070治疗10天期间或治疗终止后7天内X4嗜性病毒降低1 log 10 rlu，并描述X4嗜性病毒对应的log 10 rlu从基线至第10天的变化

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this study are to determine the safety of several dose levels of AMD11070 (with the starting dose determined by the results of A5191 administered over 10 days with HIV-infected subjects who harbor X4-tropic virus and to determine the proportion of subjects per cohort who have a ?1 log10 rlu reduction in X4-tropic virus during 10 days of AMD11070 treatment or in the 7 days following treatment discontinuation, and to describe changes from baseline to day 10 in log10 rlu corresponding to X4-tropic virus